BT Slingsby

BT Slingsby founded Catalys Pacific to transform life-sciences innovation in Japan using transpacific bioventure. He specializes in healthcare investments in the pharma sector including novel therapeutics, diagnostics and vaccines.

Prior to Catalys Pacific, he founded the Global Health Innovative Technology (GHIT) Fund – the world’s first public-private fund focused on the development of new medicines for low- and middle-income countries. In his role as CEO and Executive Director at the GHIT Fund, he deployed over 100 investments and grew the fund to $350M in capital.

Previously, BT was global head of access strategy at Eisai Co., Ltd. where he led market access strategy for global products and managed a portfolio of anti-infective clinical programs.

BT graduated from Brown University with honors, earned his M.P.H. and Ph.D. from Kyoto University and the University of Tokyo, and received his M.D. with honors from the George Washington University. In recognition of his contributions to global health, he has been awarded a Foreign Ministry Commendation from the Government of Japan. BT has authored over 50 peer-reviewed articles on medicine and public health and currently lectures at the Graduate School of Medicine at the University of Tokyo and Kyoto University.